Company ProfileWe are building an innovative IVD solution platform to screen for disease-associating molecular signatures from human immune response (HIR) through an multi-omics approach and develop these signatures into IVD solutions. We have successfully identified and validated HIR signatures for the early screening of human colorectal cancer, lung cancer and liver cancer. GCP-grade double-blind clinical trials are ongoing in reputable hospitals in China.